News
Yumanity Therapeutics and Proteostasis Therapeutics to merge and operate as Yumanity Therapeutics
Yumanity Therapeutics and Proteostasis Therapeutics, Inc. announced that the companies have entered into a definitive merger agreement. The combined company, operating under the name Yumanity Therapeutics, Inc., will leverage a common scientific expertise in the area of protein misfolding to advance Yumanity's pipeline of innovative, disease-modifying programs for neurodegenerative diseases.
Yumanity's first clinical-stage product candidate, YTX-7739, is currently in Phase 1 clinical development for the treatment and disease modification of Parkinson's disease. Yumanity is also advancing several additional candidates for other neurodegenerative disorders, including dementia with Lewy bodies, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), and frontotemporal lobar dementia (FTLD).Proteostasis plans to sell off its cystic fibrosis drugs. It also has reduced its workforce by 79%, leaving just five full-time employees.
Type: industry